UA78801C2 - Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4- 1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride - Google Patents

Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4- 1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride Download PDF

Info

Publication number
UA78801C2
UA78801C2 UA20041210897A UA20041210897A UA78801C2 UA 78801 C2 UA78801 C2 UA 78801C2 UA 20041210897 A UA20041210897 A UA 20041210897A UA 20041210897 A UA20041210897 A UA 20041210897A UA 78801 C2 UA78801 C2 UA 78801C2
Authority
UA
Ukraine
Prior art keywords
temperature
indol
crystalline
treatment
salt
Prior art date
Application number
UA20041210897A
Other languages
English (en)
Ukrainian (uk)
Inventor
Julie Kay Bush
Margaret Mary Faul
Susan Marie Reutzel-Edens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42799191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA78801(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of UA78801C2 publication Critical patent/UA78801C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UA20041210897A 2002-07-12 2003-08-07 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4- 1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride UA78801C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39597602P 2002-07-12 2002-07-12
PCT/US2003/019548 WO2004006928A1 (en) 2002-07-12 2003-07-08 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Publications (1)

Publication Number Publication Date
UA78801C2 true UA78801C2 (en) 2007-04-25

Family

ID=42799191

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041210897A UA78801C2 (en) 2002-07-12 2003-08-07 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4- 1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Country Status (21)

Country Link
US (2) US8114901B2 (https=)
EP (1) EP1523313B1 (https=)
JP (2) JP4771356B2 (https=)
KR (1) KR100687165B1 (https=)
CN (1) CN100430058C (https=)
AU (1) AU2003280958B9 (https=)
CA (1) CA2393720C (https=)
DE (1) DE60317675T2 (https=)
EA (1) EA007463B1 (https=)
EC (1) ECSP055537A (https=)
ES (1) ES2295605T3 (https=)
HR (1) HRP20050035B1 (https=)
IL (1) IL165747A (https=)
NO (1) NO330254B1 (https=)
NZ (1) NZ537137A (https=)
PE (1) PE20040652A1 (https=)
PL (1) PL373046A1 (https=)
TW (1) TWI315667B (https=)
UA (1) UA78801C2 (https=)
WO (1) WO2004006928A1 (https=)
ZA (1) ZA200500065B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5475234B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
CN102405018B (zh) 2009-03-02 2014-11-19 第七感生物系统有限公司 与血液取样相关联的技术和装置
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
WO2011163347A2 (en) 2010-06-23 2011-12-29 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
WO2012009613A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure environment for fluid transfer devices
NZ606180A (en) * 2010-09-30 2014-10-31 Wisconsin Alumni Res Found (20r,25s)-2-methylene-19,26-dinor-1α, 25-dihydroxyvitamin d3 in crystalline form
EP2992827B1 (en) 2010-11-09 2017-04-19 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
CN103874460B (zh) 2011-04-29 2016-06-22 第七感生物系统有限公司 一种用于从受验者的皮肤接收血液或其它物质的装置
JP2019525990A (ja) 2016-06-17 2019-09-12 ウニベルシダッド デ ロス アンデス 低温適応海洋種の天然資源に由来するゼラチンポリマー及びその使用
TWI777658B (zh) 2016-08-10 2022-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3625738A1 (de) * 1986-07-30 1988-02-11 Goedecke Ag 2-acyloxypropylamin-derivate, verfahren zu deren herstellung und deren verwendung
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
DE3803620A1 (de) 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5489608A (en) * 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
SE501711C2 (sv) * 1993-09-08 1995-05-02 Jimek Int Ab Sprayrör för en duktvättanordning vid en tryckpress
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
ES2236702T3 (es) * 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
AU6335600A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
WO2001030331A2 (en) * 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
AU2001271261A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
MXPA04012188A (es) * 2002-06-05 2005-07-25 Johnson & Johnson Derivados de bisindolil-maleimida como inhibidores de cinasa.

Also Published As

Publication number Publication date
AU2003280958A1 (en) 2004-02-02
US8114901B2 (en) 2012-02-14
IL165747A (en) 2010-05-17
TW200408392A (en) 2004-06-01
ECSP055537A (es) 2005-03-10
ZA200500065B (en) 2006-03-29
JP2006502115A (ja) 2006-01-19
AU2003280958B2 (en) 2008-12-18
EA200500191A1 (ru) 2005-06-30
JP5242718B2 (ja) 2013-07-24
CN100430058C (zh) 2008-11-05
NO20050676L (no) 2005-02-09
NO330254B1 (no) 2011-03-14
DE60317675D1 (de) 2008-01-03
DE60317675T2 (de) 2008-10-30
HK1075839A1 (en) 2005-12-30
JP4771356B2 (ja) 2011-09-14
KR20050021453A (ko) 2005-03-07
NZ537137A (en) 2007-11-30
KR100687165B1 (ko) 2007-02-27
HRP20050035A2 (en) 2005-04-30
CA2393720A1 (en) 2004-01-16
PE20040652A1 (es) 2004-10-05
IL165747A0 (en) 2006-01-15
EA007463B1 (ru) 2006-10-27
EP1523313A1 (en) 2005-04-20
JP2011144182A (ja) 2011-07-28
US20070270465A1 (en) 2007-11-22
CA2393720C (en) 2010-09-14
ES2295605T3 (es) 2008-04-16
HRP20050035B1 (hr) 2013-07-31
US20050288332A1 (en) 2005-12-29
AU2003280958B8 (en) 2009-02-19
PL373046A1 (en) 2005-08-08
TWI315667B (en) 2009-10-11
AU2003280958B9 (en) 2009-07-02
EP1523313B1 (en) 2007-11-21
CN1668304A (zh) 2005-09-14
WO2004006928A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
JP5242718B2 (ja) 2,5−ジオン−3−(1−メチル−1h−インドール−3−イル)−4−[1−(ピリジン−2−イルメチル)ピペリジン−4−イル]−1h−インドール−3−イル]−1h−ピロール一塩酸塩の結晶
CN116507620B (zh) Cdk4抑制剂的固体形式
US12410189B2 (en) Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production
WO2021113661A1 (en) Amorphous and polymorphic form of a specific chk1 inhibitor
AU2019260240A1 (en) Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor
KR101148580B1 (ko) Mglur5 수용체 길항제의 다형체
JP2018521095A (ja) 変異イソクエン酸デヒドロゲナーゼidh1 r132hの阻害剤
WO2024110853A1 (en) Solid forms of a fused pyridine for the treamtent of cancer
UA112899C2 (uk) Тверді форми n-((s)-2,3-дигідроксипропіл)-3-(2-фтор-4-йодфеніламіно)-ізонікотинаміду
JP2022500416A (ja) がんを処置するためのキットおよび方法
WO2025202991A1 (en) Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl)amino)-pyrrolidine-1-sulfonamide
MXPA02007150A (es) Monoclorohidrato crsitalino de 2, 5-diona-3-(1-metil -1h-indol-3-il) -4-[1-(piridin-2-ilmetil) piperidin-4-il) -1h-indol-3-il) -1h-pirrol.
WO2026076328A1 (en) Solid state forms of ulk inhibitors
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK40074209A (en) Shp2 phosphatase inhibitors and methods of making and using the same
HK1075839B (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
HK40060200A (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina